Inside these posts: Baxter

Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.


Baxter CEO’s compensation falls 20% in 2010

Baxter International Inc. Chief Executive Robert L. Parkinson Jr. received compensation valued at $11.5 million in 2010, down 20 percent from the prior year amid a sharp reduction in his annual bonus and a tumultuous year for the medical-products company. Get the full story »

FDA issues warning to Baxter over drug promotion‎

Federal health regulators have issued a warning letter to Baxter International Inc. for exaggerating the benefits of its lung drug in brochures to physicians.

The Food and Drug Administration letter cites the Deerfield, Ill.-based company for making “misleading efficacy claims” in promotional materials for its drug Aralast.

Baxter recalling Hylenex for glass particles

By Bruce Japsen | Medical product giant Baxter International Inc. and a San Diego biotech
company issued a voluntary recall of Hylenex vials after discovering
small “flake-like glass particles in a limited number of vials.”  

The recall comes less than a year after Baxter launched the product as
a new way to administer intravenous fluids to rehydrate children and
infants more quickly and efficiently. Hylenex can be administered
without the tricky search for a tiny vein.

Get the full story »

S&P lowers Baxter outlook but maintains ratings

Associated Press | Standard & Poor’s Ratings Services reduced
its outlook on Baxter International Inc. Thursday, but said Baxter’s
diverse range of products will help it deal with a recall of its drug
infusion pumps.

Standard & Poor’s said its view of Baxter’s credit is “Stable,” down
from a previous “Positive” outlook. The firm maintained its
investment-grade “A+” corporate credit rating on the company.

Get the full story »